Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 27, 2016
Pharmacy Choice - News - Generic Drugs - August 27, 2016

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 59     Next >>     Go To Page:

8/26/16 - ACETO CORP - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
We are reporting net sales of $558,524 for the year ended June 30, 2016, which represents a 2.1% increase from the $546,951 reported in the comparable prior year. Gross profit for the year ended June 30, 2016 was $142,785 and our gross margin was 25.6% as compared to gross profit of $135,434 and gross margin of 24.8% in the comparable prior year.
8/26/16 - Akorn Relaunches Ofloxacin Otic Solution
Release date- 25082016- LAKE FOREST, Ill- Akorn, Inc., a leading specialty pharmaceutical company, today announced that it has relaunched Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use. According to IMS Health, sales of Ofloxacin Otic Solution were approximately $33 million for the twelve months ended June 30,
8/26/16 - Akorn Relaunches Ofloxacin Otic Solution [Arab News (Saudi Arabia)]
-Akorn, Inc., a leading specialty pharmaceutical company, today announced that it has relaunched Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use. According to IMS Health, sales of Ofloxacin Otic Solution were approximately $33 million for the twelve months ended June 30, 2016. Akorn has manufacturing facilities
8/26/16 - Akorn to Present at Morgan Stanley Global Healthcare Conference
Release date- 25082016- LAKE FOREST, Ill- Akorn, Inc., a leading specialty generic pharmaceutical company, today announced that Akorn's CEO, Raj Rai, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference. Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing
8/26/16 - Bharat Book Bureau: Global Biopharmaceutical Market Report & Forecast
The global biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today hundreds of biopharmaceuticals have already been approved and many more are in late stages of clinical development. Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth
8/26/16 - EDITORIAL: Life-saving drug? Investigate prices [The Santa Fe New Mexican]
This medicine comes out in potentially life-threatening situations, when an allergic reaction or bee sting is sending the body into anaphylactic shock. That's why it is particularly galling that the price of the pens is soaring for no apparent reason up from about $47 for a single pen in 2007 to $284 this summer. Oh, and a consumer can no longe
8/26/16 - Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency
Release date- 25082016- BENGALURU, India and HERTFORDSHIRE, England/ PITTSBURGH, USA- Mylan N.V. and Biocon Ltd. announced today that the European Medicines Agency has accepted for review Mylan's Marketing Authorization Application for a proposed biosimilar Trastuzumab, which is used to treat certain HER2-positive breast and gastric cancers.
8/26/16 - Pfizers Involvement in EpiPens Could Complicate Drug Price Debate [Khaleej Times (United Arab Emirates)]
It is less well known, however, that while Mylan markets and prices the drug, Pfizer Inc. actually manufactures the drug and has seen increased revenues from EpiPens over the last few years. The financial relationship between the two drug companies is unclear, and Pfizer declined to elaborate. The terms of our supply agreement are confidential, sai
8/26/16 - Researchers from Hospital Center Describe Findings in Neutropenia [Zarzio, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced...
By a News Reporter-Staff News Editor at Drug Week Investigators publish new report on Leukocyte Diseases and Conditions- Neutropenia. According to news originating from Aix en Provence, France, by NewsRx correspondents, research stated, "Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment
8/26/16 - Teva Announces Launch of Generic Gleevec Tablets in the United States
By a News Reporter-Staff News Editor at Drug Week Teva Pharmaceutical Industries Ltd., announced the launch of the generic equivalent to Gleevec 1 tablets, 100 mg and 400 mg, in the United States for multiple indications approved by the FDA. With nearly 375 generic medicines available, Teva has one of the largest portfolios of FDA- approved ge
8/26/16 - UPSHER-SMITH ENTERS INTO EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT WITH EMERGING PHARMACEUTICAL COMPANY
Release date- 25082016- Maple Grove, MN- Upsher-Smith Laboratories, Inc. announced that it has entered into an exclusive agreement with an emerging pharmaceutical company to market and distribute a generic central nervous system product with U.S. sales of more than $200 million for the 12 months ending June 2016, according to IMS Health. Under the
8/26/16 - US: EpiPen costs to be slashed for some patients amid wave of criticism [EuroNews]
There s no justification for these price hikes. https://t.co/O6RbVR6Qim- H Hillary Clinton 24 August 2016. So what the FDA really needs to do is to prioritise the review of generic drugs for products that don t currently have generic on the market. As soon as the FDA approves a generic for EpiPen, the price is going to plummet 70 or 80
8/26/16 - VNDA Soars, CEMI Secures Zika Contract, EMA To Review MYL's Proposed Biosimilar
CANONSBURG- Chembio Diagnostics Inc. has been awarded up to $13.2 million U.S. Government contract for the development and commercialization of the company's rapid POC Zika test and Zika-related products. Shares of Vanda Pharmaceuticals Inc. soared more than 20% on Thursday, following a favorable verdict in the patent litigation against Roxane...
8/25/16 - Abbreviated New Drug Application SubmissionsRefuse To Receive for Lack of Justification of Impurity Limits; Guidance for Industry; Availability
SUMMARY: The Food and Drug Administration is announcing the availability of a guidance for industry entitled "Abbreviated New Drug Application SubmissionsRefuse to Receive for Lack of Justification of Impurity Limits." This guidance is intended to assist applicants preparing to submit to FDA abbreviated new drug applications and prior approval...
8/25/16 - ARENA PHARMACEUTICALS INC FILES (8-K) Disclosing Other Events
We and Eisai Inc. have received a "Paragraph IV certification" notification with respect to patents for BELVIQ listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The certification was from an Abbreviated New Drug Application for a proposed generic version of BELVIQ . In accordance with the.
8/25/16 - Biosimilars Market 2015-2022 - Global Strategic Business Report 2016: Recent Biosimilar Approvals And Pipeline Analysis
Dublin- Research and Markets has announced the addition of the "Biosimilars- Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.
8/25/16 - Biosimilars Market 2015-2022 - Global Strategic Business Report 2016: Recent Biosimilar Approvals And Pipeline Analysis - Research and Markets
Research and Markets has announced the addition of the "Biosimilars- Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Reddy's Laboratories Ltd. Eli Lilly and Company EPIRUS Biopharmaceuticals, Inc. Hospira, Inc. Intas Biopharmaceuticals Ltd
8/25/16 - EMA accepts to review Mylan and Biocon's cancer biosimilar
Mylan and Biocon, who co-developed this proposed biosimilar, anticipate that this may be the first MAA for a trastuzumab biosimilar accepted by the EMA...
8/25/16 - Global Biosimilars Strategic Business Market Report 2016-2022 - Patent Expiry of Leading Biopharmaceuticals Leads Way for Biosimilars
Research and Markets has announced the addition of the "Biosimilars- Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Reddy's Laboratories Ltd. Eli Lilly and Compa
8/25/16 - Intellipharmaceutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
The presentation may be accessed through the Investor Relations' Events and Presentations section on Intellipharmaceutics' website at www.intellipharmaceutics.com. Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and...
8/25/16 - Jubilant Life Sciences gets US approval for generic hypertension tablets [Daily News Egypt]
Jubilant Life Sciences Ltd said it received approval for its Telmisartan Tablets used to treat hypetension or high blood pressure. Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of active pharmaceutical ingredients, solid dosage formulations, radio pharmaceuticals,..
8/25/16 - Mallinckrodt to sell nuclear imaging business [St. Louis Post-Dispatch]
Aug. 24 Mallinckrodt has entered into an agreement to sell its nuclear imaging business to IBA Molecular for $690 million, the company said Wednesday. After the sale, all that will remain of Mallinckrodt's operations in the St. Louis area will be its legacy business of making generic drugs, including painkillers and active pharmaceutical ingredie
8/25/16 - Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency
BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2016/ PRNewswire/ Mylan N.V. and Biocon Ltd. announced today that the European Medicines Agency has accepted for review Mylan's Marketing Authorization Application for a proposed biosimilar Trastuzumab, which is used to treat certain HER2-positive breast and gastric cancers.
8/25/16 - Mylan, EpiPens and drug company monopolies
I almost laughed when I read those words, and I would have were it not for the company's unconscionable business practices that have enriched its executives and shareholders at the expense of desperate families across the country, as well as the U.S. Treasury. Epinephrine has been on the market for well over 100 years, costs less than $1 per dose,
8/25/16 - Mylan: EMA To Review MAA For Proposed Biosimilar Trastuzumab
CANONSBURG- Mylan N.V. and Biocon Ltd. announced the European Medicines Agency has accepted for review Mylan's Marketing Authorization Application for a proposed biosimilar Trastuzumab, which is used to treat certain HER2-positive breast and gastric cancers. The companies, which have co-developed the proposed biosimilar, anticipate this may be the.
Articles(s): 1 - 25 of 59     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415